Exact Sciences Using MDxHealth's Technology in Colon Cancer Test

MDxHealth said that Exact's decision to move forward with the test has triggered a milestone payment of an undisclosed amount. The company is also entitled to royalties on sales of the test once it is commercialized.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.